<DOC>
	<DOCNO>NCT02403271</DOCNO>
	<brief_summary>This Phase 1b/2 , multi-center study assess safety efficacy ibrutinib combination durvalumab ( MEDI4736 ) subject relapse refractory solid tumor .</brief_summary>
	<brief_title>A Multi-Center Study Ibrutinib Combination With MEDI4736 Subjects With Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Pathologically confirm Nonsmall cell lung cancer ( NSCLC , adenocarcinoma squamouscell carcinoma ) 2 . Relapsed refractory disease ( Stage III IV ) : NSCLC must fail least 1 prior treatment . 3 . Measurable lesion RECIST 1.1 4 . Adequate hematologic function : ANC &gt; 1500 cells/mm3 Platelet count &gt; 100,000 cells/mm3 HGB &gt; 9.0 g/dL 5 . Adequate hepatic renal function : AST ALT ≤2.5 x ULN subject without liver metastasis ≤3.5 x ULN subject liver metastasis Bilirubin ≤1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin ) Creatinine ≤2.0 x ULN Creatinine Clearance ≥40 mL/min 6 . PT/INR &lt; 1.5 x ULN PTT/ aPTT &lt; 1.5 x ULN 1 . Mixed small cell NSCLC histology 2 . A history CNS involvement except follow : Subjects previously treat CNS metastasis adequately treat whole brain radiotherapy , neurologically stable , require corticosteroid symptomatic management least 14 day prior first dose study drug . There must clear evidence radiographically active disease least 90 day prior enrollment . 3 . Antitumor therapy within 21 day study Day 1 4 . Prior treatment ibrutinib BTK inhibitor antiCD137 CTLA4 antibody . The following exception criterion : Subjects previously treat antiPD1 , antiPDL1 , antiPDL2 antibody . 5 . History allogeneic organ transplant 6 . Treatment strong cytochrome P450 ( CYP ) 3A inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Durvalumab ( MEDI4736 )</keyword>
	<keyword>Relapsed Refractory Solid Tumor</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Squamous</keyword>
	<keyword>Squamous NSCLC</keyword>
	<keyword>Squamous Non-Small Cell Lung Cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>IMBRUVICA®</keyword>
	<keyword>Tumor Immunotherapy</keyword>
	<keyword>Anti-PD-L1</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>